期刊
NEURODEGENERATIVE DISEASE MANAGEMENT
卷 9, 期 1, 页码 39-46出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nmt-2018-0034
关键词
dyskinesia; levodopa; Parkinson's disease; quality of life
资金
- AbbVie Inc., North Chicago, IL, USA
- National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- Parkinson's UK
- PDNMG
- EU Horizon 2020
- IMI initiative
- UCB
- Britannia
- AbbVie
- GSK Pharmaceuticals
- Boehringer Ingelheim
- Neuronova
- Mundipharma
Aim: To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden. Patients & methods: Post hoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and >= 4 h/day of levodopa-induced dyskinesia at baseline. Results & conclusions: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with >= 4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1.6 h in patients with <4 h baseline dyskinesia. Quality of life improved in both subgroups. Adverse drug reactions occurred at similar rates in both subgroups. Despite increases in levodopa dose, levodopa-carbidopa intestinal gel treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson's disease patients with high baseline dyskinesia burden.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据